Web Cast Announcing Promising News from ASCO for Early Breast Cancer Patients

    Orlando, Florida (ots/PRNewswire) -

    - Landmark Study Big 1-98 Shows Letrozole Offers Greater Protection from Recurrence of Early Breast Cancer than Tamoxifen

    - Web Cast Briefing Available at 17 May 2005 8:00 AM EDT http://www.ibcsg.org/index.shtm

    Newly updated results of the independent Breast International Group 1-98 trial just released at ASCO show initial treatment with letrozole, also known as Femara(R), offers significantly greater post-surgery protection against breast cancer recurrence than does tamoxifen, in postmenopausal women with early breast cancer.

@@start.t1@@      Findings Confirm:
        - Letrozole out-performed tamoxifen with a 19% (p=0.003) reduction in
          risk of breast cancer recurrence
        - Letrozole demonstrated greater disease free survival in two patient
          subgroups that are at highest risk:
          - Node-positive: 29% risk reduction
          - Prior chemotherapy: 30% risk reduction
        - Letrozole reduced the risk of cancer spreading to other parts of the
          body (distant metastases) by 27% (p=0.0012)@@end@@

    This Web cast presents updated BIG 1-98 trial results presented at the 2005 annual meeting of the American Society for Clinical Oncology (ASCO) and an understanding of what the trial results mean for patients.

@@start.t2@@      WHERE:        Click on the following link and view the Web cast data
                        presentation: http://www.ibcsg.org/index.shtm
      WHO:          Dr. John Forbes, University of Newcastle, Newcastle Mater
                        Hospital, Australia and BIG 1-98 Investigator
      CONTACTS:  For questions or to arrange an interview with Dr. John Forbes,
                        please contact:
                        Rum Ekhtiar                                 Nadia Munarini, PhD
                        Ruder Finn                                  IBCSG
                        Phone:  +1-212-593-5821              Phone:  +41-31-389-92-27
                        Mobile: +1-917-331-1690              Mobile: +41-79-207-45-82@@end@@

    Web site: http://www.ibcsg.org/index.shtm

ots Originaltext: IBCSG
Im Internet recherchierbar: http://www.presseportal.ch

Rum Ekhtiar of Ruder Finn, +1-212-593-5821, Mobile: +1-917-331-1690,
for IBCSG; or Nadia Munarini, PhD of IBCSG, +41-31-389-92-27, Mobile:

Weitere Meldungen: IBCSG

Das könnte Sie auch interessieren: